Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas.

Authors: Karki, Keshav; Li, Xi; Jin, Un-Ho; Mohankumar, Kumaravel; Zarei, Mahsa; Michelhaugh, Sharon K; Mittal, Sandeep; Tjalkens, Ronald; Safe, Stephen

Published In J Neurooncol, (2020 Jan)

Abstract: The orphan nuclear receptor 4A2 (NR4A2) has been extensively characterized in subcellular regions of the brain and is necessary for the function of dopaminergic neurons. The NR4A2 ligand, 1,1-bis (31-indoly1)-1-(p-chlorophenyl)methane (DIM-C-pPhCl) inhibits markers of neuroinflammation and degeneration in mouse models and in this study we investigated expression and function of NR4A2 in glioblastoma (GBM).Established and patient-derived cell lines were used as models and the expression and functions of NR4A2 were determined by western blots and NR4A2 gene silencing by antisense oligonucleotides respectively. Effects of NR4A2 knockdown and DIM-C-pPhCl on cell growth, induction of apoptosis (Annexin V Staining) and migration/invasion (Boyden chamber and spheroid invasion assay) and transactivation of NR4A2-regulated reporter genes were determined. Tumor growth was investigated in athymic nude mice bearing U87-MG cells as xenografts.NR4A2 knockdown and DIM-C-pPhCl inhibited GBM cell and tumor growth, induced apoptosis and inhibited migration and invasion of GBM cells. DIM-C-pPhCl and related analogs also inhibited NR4A2-regulated transactivation (luciferase activity) confirming that DIM-C-pPhCl acts as an NR4A2 antagonist and blocks NR4A2-dependent pro-oncogenic responses in GBM.We demonstrate for the first time that NR4A2 is pro-oncogenic in GBM and thus a potential druggable target for patients with tumors expressing this receptor. Moreover, our bis-indole-derived NR4A2 antagonists represent a novel class of anti-cancer agents with potential future clinical applications for treating GBM.

PubMed ID: 31754919 Exiting the NIEHS site

MeSH Terms: Animals; Antineoplastic Agents/pharmacology; Apoptosis; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic/drug effects*; Glioblastoma/drug therapy; Glioblastoma/metabolism; Glioblastoma/pathology*; Humans; Indoles/pharmacology*; Mice; Mice, Nude; Nuclear Receptor Subfamily 4, Group A, Member 2/antagonists & inhibitors*; Nuclear Receptor Subfamily 4, Group A, Member 2/genetics; Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism; Prognosis; RNA, Small Interfering/genetics; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

to Top